SEC Form 4 · accession 0001209191-18-064099
CRISPR Therapeutics AG · CRSP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
Pharmaceuticals Inc / Ma Vertex
10% Owner
Vertex Pharmaceuticals (Europe) Ltd
10% Owner
Period of report
Dec 21, 2018
Accepted (ET)
Dec 26, 2018 · 4:35 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001674416
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1,F2 | Dec 21, 2018 | P | 22,742 | $22.5784 | A | 5,272,742 | D | |
| Common SharesF1,F3 | Dec 24, 2018 | P | 2,603 | $22.9147 | A | 5,275,345 | D | |
| Common SharesF1,F4 | Dec 24, 2018 | P | 11,742 | $23.1766 | A | 5,287,087 | D | |
| Common SharesF1,F5 | Dec 24, 2018 | P | 53,655 | $24.9687 | A | 5,340,742 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares are directly held by Vertex Pharmaceuticals (Europe) Limited ("Vertex Europe"). Vertex Europe is an indirect wholly owned subsidiary of Vertex Pharmaceuticals Inc. Vertex Pharmaceuticals Inc. may be deemed to beneficially own the shares owned directly by Vertex Europe.
- F2Represents the weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.46 and $22.70.
- F3Represents the weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.69 and $23.00.
- F4Represents the weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.02 and $23.25.
- F5Represents the weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.82 and $25.00.